Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

102 results about "Biomarker panel" patented technology

DNA methylation biomarker combination for prostate cancer detection and application of DNA methylation biomarker combination

The invention discloses a DNA methylation biomarker combination for prostate cancer detection and application of the DNA methylation biomarker combination, and belongs to the technical field of biological medicine. The DNA methylation biomarker combination comprises a combination of methylation sites indicated by CG in the SEQ ID NO: 1 sequence of the USP44 gene and the SEQ ID NO: 2 sequence of the HIF3A gene. It is reported for the first time that the methylation levels of the USP44 gene and the HIF3A gene are detected at the same time to conduct auxiliary diagnosis on the prostatic cancer, a sample urine detection result shows that the sensitivity is 97.14%, the specificity is 97.78%, and the non-invasive and reliable prostatic cancer detection method is provided and has good application prospects in early screening of the prostatic cancer.
Owner:WUHAN YZY MEDICAL SCI & TECH

Compositions and methods for diagnosing early-stage precancerous colorectal advanced adenomas or cancers

The present disclosure provides methods and compositions, e.g., kits, for diagnosing colorectal cancer or precancerous colorectal advanced adenomas based on a subject's biomarker panels in a biological sample (e.g., a feces sample or a blood sample).
Owner:EL CAPITAN BIOSCIENCES INC

Combined detection and application of biomarkers

The present invention belongs to the field of biomedicine, and specifically relates to a combination and application of joint detection of biomarkers for Alzheimer's disease. The present invention provides an application of a biomarker group in detecting Alzheimer's disease, characterized in that the biomarker group includes: a) at least two of APOE4, GDF-15, UCH-L1 and PF4; or b) at least one of APOE4, GDF-15, UCH-L1 and PF4, as well as phosphorylated Tau protein and total Tau protein. The present invention also provides a kit for detecting Alzheimer's disease. The present invention contributes to a more effective detection and diagnosis of Alzheimer's disease, and provides a new path for the detection and prevention of AD.
Owner:ZYBIO INC

Metabolic biomarker combination for depression diagnosis

The invention discloses a metabolic biomarker combination for diagnosing depression. The metabolic biomarker combination comprises proline, betaine, alanine, tryptophan, kynurenine, 5-hydroxytryptamine, creatine, succinic acid, taurine and 2-hydroxybutyric acid. Based on a metabolic biomarker combination, an optimal diagnosis model is screened through a machine learning model algorithm, and the kit for depression diagnosis is constructed.
Owner:NANJING LIKANG PHARMACEUTICAL TECHNOLOGY CO LTD

Biomarker combination and application thereof in predicting embryo quality

The invention discloses a biomarker combination and application thereof in predicting embryo quality. Wherein the biomarker combination comprises small molecule non-coding RNA (Ribonucleic Acid) with nucleotide sequences as shown in SEQ ID NO.1-3; or micromolecule non-coding RNA as shown in SEQ ID NO.1-8; or micromolecular non-coding RNA as shown in SEQ ID NO.1-13. The invention also discloses a method for preparing the micromolecular non-coding The biomarker combination disclosed by the invention not only contains miRNA, but also contains multiple types of sncRNA such as tsRNA, snRNA, Y RNA, snoRNA and the like, and the biomarker combination has the characteristic of obviously distinguishing the embryo quality. When the biomarker combination is used for predicting the embryo quality, only an embryo culture solution is needed, and as a non-invasive sample collection operation, the shape and subsequent development of the embryo are not influenced. Meanwhile, the invention also provides a construction method and a prediction method of the embryo quality prediction model, and the final model has high sensitivity and high specificity, thereby providing guidance for embryo screening.
Owner:THE UNIVERSITY OF HONG KONG SHENZHEN HOSPITAL

Pancoronavirus biomarker panel

PCT designated stage expiredWO2025006633A1Microbiological testing/measurementBiomarker panelAssay
The present disclosure provides pancoronavirus biomarker panels that can be used to detect a wide variety of characterized coronavirus strains and, in some embodiments, emerging or novel coronavirus strains. In certain embodiments, this detection can be carried out in a single, highly-multiplexed nucleic acid amplification assay.
Owner:CEPHEID INC

Biomarker composition and application thereof in glioblastoma screening

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker composition and application thereof in glioblastoma screening. The biomarker combination is prepared from one or more of the following metabolites: L-aspartic acid, 3-phosphoric acid-D-glyceric acid, 2-phosphoric acid glyceric acid, hexadecanamide ethanol, D-red sphingosine-1-phosphoric acid, L-goose carnosine, L-alanine-L-lysine, docosahexaenoic acid, leukotriene C4 and urea glutaric acid. According to the invention, a patient with glioblastoma is identified through a plurality of biomarkers, so that the accuracy and comprehensiveness of diagnosis are improved. And the detection can be completed by acquiring body fluid, the sampling is convenient, and the kit is suitable for screening the glioblastoma patients in a large scale, and can effectively overcome the individual difference of the glioblastoma patients.
Owner:ZHUJIANG HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY +1

Biomarkers and methods relating to Alzheimer's disease

Alzheimer's disease, the most common cause of dementia in older individuals, is a debilitating neurodegenerative disease for which there is currently no cure. In the past, AD could only be definitively diagnosed by brain biopsy or upon autopsy after a patient died. These methods, which demonstrate the presence of the characteristic plaque and tangle lesions in the brain, are still considered the gold standard for the pathological diagnoses of AD. However, in the clinical setting brain biopsy is rarely performed and diagnosis depends on a battery of neurological, psychometric and biochemical tests, including the measurement of biochemical markers such as the ApoE and tau proteins or the beta-amyloid peptide in cerebrospinal fluid and blood. The present invention discloses and describes panels of makers that are differentially expressed in the disease state relative to their expression in the normal state and, in particular, identifies and describes panels of makers associated with neurocognitive disorders. Such biomarker panel might have considerable value in triaging patients with early memory disorders to yet more specific but more invasive and costly approaches such as molecular markers in CSF and on PET imaging in clinical trials and possibly in clinical practice.
Owner:ELECTROPHORETICS LTD +1

Detection of bladder cancer

The present invention provides a method for detecting the presence of or risk of bladder cancer in a female patient, the method comprising the steps of: detecting the presence of a biomarker panel in a sample isolated from a female patient, the biomarker panel comprising IL-13 and IL-12p70 and one or more biomarkers selected from the group consisting of BTA, midkine, PAI-1 / tPA, 8OHdG, CEA, CK18, Fibrillin, Creatinine, CXCL16, Cystatin B, Cystatin C, d-dimer, EGF, FAS, HAD, IL-1a, IL-1b, IL-4, IL-6, IL-7, IL-8, MCP-1, Microalbumin, MMP9 NGAL, MMP9 TIMP1, NGAL, NSE, Progranulin, TUP, TGFB1, Thrombomodulin, sTNFR1, TPA, VEGF and Triglyceride, and / or the concentration of albumin / microalbumin / protein to creatinine in a sample isolated from a female patient, expressed as an albumin:creatinine ratio; and assessing the result and comparing it to a normal control, wherein an increase in the presence of the biomarkers compared to the normal control indicates the presence or risk of cancer in the patient from which the sample was isolated.
Owner:RANDOX LAB LTD

Biomarker combination for predicting Parkinson's disease classification and progression and its use

The present invention provides a biomarker combination for predicting the classification and progression of Parkinson's disease and uses thereof, wherein the biomarker combination comprises a single nucleotide polymorphism (SNP) selected from: rs6808178, rs591323 or a combination of the two, and the reference genome used by the SNP is the GRCh37 / hg19 human reference genome. The biomarker combination of the present invention and uses thereof can predict the clinical classification of Parkinson's disease and the progression of motor function and cognitive decline.
Owner:BEIJING TIANTAN HOSPITAL AFFILIATED TO CAPITAL MEDICAL UNIV

Screening systems and methods for HPV-associated cervical disease

Devices and methods described herein provide improved methods of screening for cervical disease. In certain embodiments, a sample transfer and preparation vial is provided, enabling self-collection and pre-processing of cervical samples to expedite sample processing and eliminate the need for a patient to travel to a medical facility for screening. In certain embodiments, an analysis cartridge having a multiplexed biomarker panel and an immunoassay-based analyzer are provided for sample analysis. The multiplexed biomarker panel provides high sensitivity and specificity to enable effective screening with a single procedure and thus, eliminates the need for multiple tests. In certain embodiments, a method of screening for cervical disease is provided, utilizing the aforementioned multiplexed biomarker panel. The method includes detecting levels of at least two biomarkers in a cervical sample, wherein one of the biomarkers is an oncoprotein from a high-risk strain of human papilloma virus (HPV) and another is a cellular protein.
Owner:ONCOGENESIS

Diabetic retinopathy diagnosis and analysis platform based on double-body fluid and method for analyzing biological fluid sample by using diabetic retinopathy diagnosis and analysis platform

The invention discloses a diabetic retinopathy diagnosis and analysis platform based on double body fluids and a method for analyzing a biological fluid sample by using the diabetic retinopathy diagnosis and analysis platform, and relates to the field of biological diagnos.The diabetic retinopathy diagnosis and analysis platform comprises an acquisition and analysis module and a machine learning module, the acquisition and analysis module acquires mass spectrum data of a biological sample through a mass spectrum system for analysis, and the machine learning module analyzes and processes the acquired mass spectrum data of the biological sample, constructs a diabetic retinopathy biomarker panel, and analyzes the diabetic retinopathy biomarker panel to obtain the diabetic retinopathy biomarker. The invention also comprises a method for analyzing a biological fluid sample by using the analysis platform, the biological fluid sample comprises vitreous humor and plasma, and the nanoparticles are used as a matrix of the biological fluid sample for mass spectrum data acquisition. The invention provides a rapid, stable, reliable and high-sensitivity vitreous humor metabonomics detection method and system.
Owner:SHANGHAI JIAOTONG UNIV

Biomarker panels for guiding dysregulated host response therapy

To provide a method for identifying a therapy recommendation for a subject exhibiting dysregulated host response.SOLUTION: A classification of the subject of subtype A, subtype B, or subtype C is obtained. The therapy recommendation for the subject is identified based at least in part on the classification. Responsive to the classification of the subject comprising the subtype A, the therapy recommendation can be no immunosuppressive therapy. Responsive to the classification of the subject comprising the subtype B, the therapy recommendation can be no therapy recommendation, immune stimulation therapy, suppression of immune regulation therapy, blocking of immune suppression therapy, blocking of complement activity therapy, and / or anti-inflammatory therapy. Responsive to the classification of the subject comprising the subtype C, the therapy recommendation can be no therapy recommendation, immune stimulation therapy, suppression of immune regulation therapy, blocking of immune suppression therapy, modulators of coagulation therapy, and / or modulators of vascular permeability therapy.SELECTED DRAWING: Figure 1A
Owner:ENDPOINT HEALTH INC

Epigenetic modification of select genes as markers of hypersomnolence

Differentially methylated positions associated with hypersomnolence, idiopathic hypersomnia, and long sleep time are provided herein along with biomarker panels thereof and methods of diagnosing and providing a prognosis of hypersomnolence, idiopathic hypersomnia, and long sleep time using said differentially methylated positions.
Owner:WISCONSIN ALUMNI RES FOUND

Biomarker panel for identifying aggressive prostate cancer

The present invention provides methods for diagnosing aggressive prostate cancer, including but not limited to methods for distinguishing between aggressive and non-aggressive forms of prostate cancer, and methods for detecting aggressive prostate cancer based on comparison with a mixed control population of subjects with non-aggressive prostate cancer or without prostate cancer.
Owner:MINOMIC INT

Biomarker panel, kit and system for predicting poor prognosis in patients with ischemic stroke

The present invention discloses a biomarker, a kit and a system for predicting poor prognosis of ischemic stroke patients, which relate to the technical field of molecular diagnosis. The biomarker group disclosed by the present invention includes a protein biomarker group and a single nucleotide polymorphism (SNP) biomarker group. Using the biomarker group, kit and system provided by the present invention can better predict the risk of death or severe disability occurring 3 months after the onset of ischemic stroke patients, so as to early identify high-risk patients with poor prognosis of ischemic stroke, and guide doctors to take corresponding treatment and nursing measures to prevent the occurrence of death or severe disability after the onset of ischemic stroke patients, which has important clinical and public health significance.
Owner:SUZHOU UNIV

Urinary biomarkers for active lupus nephritis and methods of use thereof

PendingUS20240418715A1Disease diagnosisBiological testingBiomarker panelUrinary biomarkers
Provided are urinary biomarker panels, kits and devices for detecting active Lupus Nephritis (ALN) comprising a plurality of biomarker detection agents, wherein each biomarker detection agent is specific for a corresponding target biomarker, the target biomarkers consisting of Adiponectin, MCP-1, sVCAM-1, and PF4, and none, one or both of vWF and IL-15, and optionally one or more control biomarkers. Also provided are methods and uses of the target biomarkers including methods of detecting acute lupus nephritis (ALN), monitoring ALN, predicting treatment outcome and treating ALN.
Owner:ARCHER AVIATION INC +1

Biomarkers and methods for predicting preterm birth

The disclosure provides biomarker panels, methods and kits for determining the probability for preterm birth in a pregnant female. The present disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing in the future or presently suffering from preterm birth relative to matched controls. The present disclosure is further based, in part, on the unexpected discovery that panels combining one or more of these proteins and peptides can be utilized in methods of determining the probability for preterm birth in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preterm birth, monitoring of progress of preterm birth in a pregnant female, either individually or in a panel of biomarkers.
Owner:SERA PROGNOSTICS INC

Machine learning method for curating biomarker panel, for screening of cancer(s) and system therefor

Disclosed is a machine learning method for curating biomarker panel, for screening of cancer(s) and system therefor, addressing the critical need for early detection through a combination of innovative biomarker research, advanced computational algorithms and integration with existing healthcare infrastructure. The biomarker panel is curated to facilitate pan-cancer screening of the patient with high sensitivity and specificity using the ML method deploying MoE (Mixture of Expert) models for accurate screening, thereby enhancing diagnostic accuracy and also empowering clinicians with actionable insights, thereby improving patient prognosis and facilitating personalized treatment strategies.
Owner:BIOMARKIQ SCIENTIFIC TECHNOLOGIES PTE LTD

Tumor early screening expiration VOCs marker identification and verification method based on machine learning

The invention discloses a machine learning-based tumor early screening expiration VOCs marker identification and verification method. The method comprises the steps of obtaining and processing high-dimensional full-spectrum expiration VOCs data; a generalized linear model is adopted to evaluate the influence of the queue correlation difference on the expiratory VOCs data, and VOCs with significant interaction are removed; screening potential expired VOCs biomarkers with significant difference between an experimental group and a control group by adopting a difference volcano plot method in which a kernel weighting function is introduced; a Boruta feature screening algorithm based on a random forest is adopted, and an expiration VOCs biomarker panel most related to the tumor is constructed; and evaluating the tumor diagnosis and grading performance of the expired VOCs biomarker panel by adopting a machine learning algorithm based on multiple underlying logics. According to the method, a marker panel construction process based on a machine learning algorithm is created, and a biomarker panel suitable for various algorithms is accurately and efficiently captured from massive expired VOCs.
Owner:SMART SMELL FUTURE (WUXI) TECHNOLOGY CO LTD

Biomarker panel for sepsis encephalopathy

ActiveUS12613250B2Disease diagnosisBiological testingGlial fibrillary acidic proteinBiomarker panel
This invention provides methods of detecting biomarkers in the biofluid of sepsis-associated encephalopathy (SAE) patients, including but not limited to glial fibrillary acidic protein (GFAP), ubiquitin C-terminal hydrolase LI, Tan protein, Neurofilament light chain (NF-L), myelin basic protein (MBP), secretogranin, Copeptin, total all-spectrin, all-spectrin breakdown products (SBDP, including SBDP145, SBDP150, SBDP120 all-spectrin N-terminal fragment or SBDP150N), neuron specific enolase (NSE), mature brain derived neurotrophic factor (BDNF), and full-length Pro-BDNF. These biomarker peptides are markers of axonal and blood brain barrier integrity which can be used to diagnose SAE and to assess and predict cognitive performance and outcomes in acute presentations of sepsis.
Owner:UNIV OF FLORIDA RESEARCH FOUNDATION INC

Biomarker combination for Alzheimer's disease and related diseases and application thereof

The invention discloses a biomarker combination for early diagnosis, prediction and / or detection of Alzheimer's disease and related diseases. The combination includes an adhesion molecule having an Ig-like domain 2, a lipid transfer inhibitor, a calcium binding protein 1, CD302, a cysteine-rich transmembrane BMP modulator, a C-X3-C motif chemokine ligand, an statin subunit beta B, a MANSC inclusion domain 1, a neurofilament light chain, a protein tyrosine phosphatase receptor type N2, and a conjugate thereof. And one or more of SLIT and NTRK-like family protein 6 and nerve growth factor induction protein. The model constructed by the combination is high in accuracy, has good sensitivity and specificity, and is helpful for early discovery and diagnosis of Alzheimer's disease, AD-derived subjective cognitive decline or mild cognitive impairment.
Owner:NANJING DRUM TOWER HOSPITAL

Biomarker screening method based on broad-target metabolomics and machine learning and its selected chronic kidney disease biomarker panel and application

The present invention discloses a biomarker screening method based on broad-target metabolomics and machine learning, and its selected chronic kidney disease biomarker group and application. The present invention is used to screen biomarkers and construct an optimal prediction model. It uses machine learning methods to process high-throughput, high-dimensional, and high-correlation metabolite abundance matrices determined by metabolomics. Through the steps of feature reconstruction, feature screening, model construction, and model screening, efficient biomarker screening and construction of an optimal prediction model can be achieved. Using this method, 7 metabolites were screened out from the plasma of patients with chronic kidney disease as biomarkers, and a prediction model was constructed to distinguish patients with chronic kidney disease in different stages. The average area under the curve of the prediction model can reach 0.99. The present invention provides a streamlined operation tool for processing complex broad-target metabolomics data, which can efficiently screen out biomarkers and build a prediction model with excellent prediction performance.
Owner:WUHAN UNIV

Respiratory biomarker panel

The present disclosure provides a set of primers and optional probes for identifying the presence of α-coronavirus, β-coronavirus, SARS-CoV-2, adenovirus, Chlamydia pneumoniae, Influenza A, Influenza B, metapneumovirus, rhinovirus / enterovirus, mycoplasma, Bordetella spp., parainfluenza, and respiratory syncytial virus (RSV), which can be included with (e.g., in at kit) or in a cartridge for automated detection of these pathogens by nucleic acid amplification. This disclosure also provides related detection methods, as well as cartridges, systems, and kits useful in such methods.
Owner:CEPHEID INC +2

Biomarkers for predicting multiple sclerosis disease activity

PendingAU2020341564B2Biomarker panelBiologic marker
Disclosed herein are methods for analzying quantitative expression values of biomarkers of a biomarker panel for determining disease activity in a human subject. Further disclosed herein are kits for measuring quantitatative expression values of the markers as well as computer systems and software embodiments of predictive models for determining disease activity in human subjects based on the qualitative expression values of the markers.
Owner:OCTAVE BIOSCIENCE INC

Biomarker panels and methods for predicting preeclampsia

The present disclosure provides biomarker panels, methods and kits for determining the probability for preeclampsia in a pregnant female, including preterm preeclampsia or preeclampsia at any gestational age. The disclosure is based, in part, on the discovery that certain proteins and peptides in biological samples obtained from a pregnant female are differentially expressed in pregnant females that have an increased risk of developing, in the future, or presently suffering from, preeclampsia relative to matched controls. The disclosure is also partially based on the unexpected discovery that panels combining one or more of these proteins / peptides can be utilized in methods of determining the probability for preeclampsia in a pregnant female with relatively high sensitivity and specificity. These proteins and peptides disclosed herein serve as biomarkers for classifying test samples, predicting a probability of preeclampsia, monitoring of progress of preeclampsia, either individually or in a panel of biomarkers.
Owner:SERA PROGNOSTICS INC